Clinical Trial Update: Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing second-line oxaliplatin plus irinotecan versus irinotecan alone in pancreatic cancer refractory to gemcitabine and S-1; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)
• Gemzar (gemcitabine)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED